| 39.95 0.15 (0.38%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 46.69 | 1-year : | 54.54 |
| Resists | First : | 39.97 | Second : | 46.69 |
| Pivot price | 39.37  |
|||
| Supports | First : | 37.61 | Second : | 36.15 |
| MAs | MA(5) : | 39.8 |
MA(20) : | 39.1 |
| MA(100) : | 31.54 |
MA(250) : | 23.57 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 98.9 |
D(3) : | 98.2 |
| RSI | RSI(14): 69 | |||
| 52-week | High : | 39.97 | Low : | 9.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ISEE ] has closed below upper band by 15.2%. Bollinger Bands are 65.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 39.98 - 40.18 | 40.18 - 40.31 |
| Low: | 39.46 - 39.73 | 39.73 - 39.91 |
| Close: | 39.56 - 39.97 | 39.97 - 40.23 |
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Tue, 11 Jul 2023
Astellas Completes Acquisition of Iveric Bio - PR Newswire
Tue, 30 May 2023
Iveric bio, Still A 5+% Opportunity (NASDAQ:ISEE) - Seeking Alpha
Mon, 01 May 2023
ISEE Stock Nabs $5.9 Billion Deal Ahead Of First Potential Approval - Investor's Business Daily
Mon, 01 May 2023
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' - Yahoo Finance
Sun, 30 Apr 2023
Astellas Enters into Definitive Agreement to Acquire Iveric Bio - PR Newswire
Sun, 23 Apr 2023
Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented ... - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 138 (M) |
| Shares Float | 137 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 109.3 (%) |
| Shares Short | 16,640 (K) |
| Shares Short P.Month | 11,850 (K) |
| EPS | -1.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.7 % |
| Return on Equity (ttm) | -55.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.85 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -177 (M) |
| Levered Free Cash Flow | -98 (M) |
| PE Ratio | -22.45 |
| PEG Ratio | 0.5 |
| Price to Book value | 11.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -31.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|